Koblan, Luke W. http://orcid.org/0000-0003-2814-4412
Arbab, Mandana
Shen, Max W. http://orcid.org/0000-0002-4226-1861
Hussmann, Jeffrey A. http://orcid.org/0000-0002-7778-9893
Anzalone, Andrew V.
Doman, Jordan L. http://orcid.org/0000-0002-9887-0391
Newby, Gregory A. http://orcid.org/0000-0001-7869-2615
Yang, Dian
Mok, Beverly
Replogle, Joseph M. http://orcid.org/0000-0003-1832-919X
Xu, Albert http://orcid.org/0000-0001-5938-561X
Sisley, Tyler A. http://orcid.org/0000-0002-7711-6234
Weissman, Jonathan S. http://orcid.org/0000-0003-2445-670X
Adamson, Britt http://orcid.org/0000-0002-9451-5819
Liu, David R. http://orcid.org/0000-0002-9943-7557
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (UG3AI150551, U01AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG009490)
Howard Hughes Medical Institute (Liu investigatorship)
Article History
Received: 4 January 2021
Accepted: 30 April 2021
First Online: 28 June 2021
Change Date: 18 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-023-02028-8
Competing interests
: J.A.H. is a consultant for Tessera Therapeutics. J.M.R. is a consultant for Maze Therapeutics. J.S.W. is a consultant for, and holds equity in, Maze Therapeutics, Chroma Medicine and KSQ Therapeutics. B.A. was a member of a ThinkLab Advisory Board for, and holds equity in, Celsius Therapeutics. D.R.L. is a consultant for, and holds equity in, Beam Therapeutics, Prime Medicine, Pairwise Plants and Chroma Medicine. The remaining authors declare no competing interests.